Samaritan Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1994-01-01
- Employees
- 11
- Market Cap
- -
SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients
Phase 2
- Conditions
- HIV InfectionsHuman Immunodeficiency Virus
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2006-10-27
- Lead Sponsor
- Samaritan Pharmaceuticals, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT00299897
- Locations
- 🇺🇸
Therafirst Medical Centers, Fort Lauderdale, Florida, United States
🇺🇸Triple O Medical Servcies, West Palm Beach, Florida, United States
🇺🇸Infectious Disease of Central Florida, Orlando, Florida, United States
A Dose Response and Safety Study of Procaine HCl in HIV-Infected Patients
Phase 1
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2006-04-03
- Lead Sponsor
- Samaritan Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT00299338
- Locations
- 🇺🇸
AIDS Research Alliance of West Hollywood, West Hollywood, California, United States
A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients
Phase 2
- Conditions
- HIV Infections
- First Posted Date
- 2005-06-08
- Last Posted Date
- 2006-03-22
- Lead Sponsor
- Samaritan Pharmaceuticals, Inc
- Target Recruit Count
- 32
- Registration Number
- NCT00113412
- Locations
- 🇺🇸
Therafirst Medical Centers, Fort Lauderdale, Florida, United States
🇺🇸Orlando Immunology Center, Orlando, Florida, United States
🇺🇸University of Texas Health Science Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath